Inclusion of residual tissue in biobanks: opt-in or opt-out?

Residual samples are an important source of tissue for biobanks. They refer to leftover tissue that is obtained in the course of clinical care. Residual samples can be included through an opt-in method--that is, a person explicitly expresses consent to include residual tissue--or an opt-out method--...

Full description

Bibliographic Details
Main Authors: Noor A A Giesbertz, Annelien L Bredenoord, Johannes J M van Delden
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Biology
Online Access:http://europepmc.org/articles/PMC3415320?pdf=render
_version_ 1818367443177832448
author Noor A A Giesbertz
Annelien L Bredenoord
Johannes J M van Delden
author_facet Noor A A Giesbertz
Annelien L Bredenoord
Johannes J M van Delden
author_sort Noor A A Giesbertz
collection DOAJ
description Residual samples are an important source of tissue for biobanks. They refer to leftover tissue that is obtained in the course of clinical care. Residual samples can be included through an opt-in method--that is, a person explicitly expresses consent to include residual tissue--or an opt-out method--that is, the tissue is stored unless a person explicitly refuses. At the moment there is a renewed interest in the appropriate method for the inclusion of residual samples in biobanks. The expansion of biobanks and rapid developments in biomedical research underscore the need to evaluate the proper procedure. In this article we revisit the arguments in favor and against opt-in and opt-out methods for residual tissue research. We conclude firstly that an opt-out method is only justifiable when certain conditions are met: (1) awareness has to be raised, (2) sufficient information has to be provided, and (3) a genuine possibility to object has to be offered. An opt-out procedure that fulfills these conditions can be called a "thick" opt-out method. As a consequence, the dichotomy between opt-in and opt-out is less stark than usually suggested, as both methods require a certain amount of effort. Secondly, we conclude that because of the diversity of tissue and research, not every situation can be treated alike. There are at least four situations that require opt-in procedures: (1) research with higher risks or increased burdens, (2) the use of controversial or high-impact techniques, (3) research on sensitive tissue types, and (4) research involving vulnerable patients. We suggest that further interdisciplinary debate should answer the question when to opt-in or when to opt-out.
first_indexed 2024-12-13T22:52:08Z
format Article
id doaj.art-2e29d956c4814ff09af7b3af0875b344
institution Directory Open Access Journal
issn 1544-9173
1545-7885
language English
last_indexed 2024-12-13T22:52:08Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Biology
spelling doaj.art-2e29d956c4814ff09af7b3af0875b3442022-12-21T23:28:35ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852012-01-01108e100137310.1371/journal.pbio.1001373Inclusion of residual tissue in biobanks: opt-in or opt-out?Noor A A GiesbertzAnnelien L BredenoordJohannes J M van DeldenResidual samples are an important source of tissue for biobanks. They refer to leftover tissue that is obtained in the course of clinical care. Residual samples can be included through an opt-in method--that is, a person explicitly expresses consent to include residual tissue--or an opt-out method--that is, the tissue is stored unless a person explicitly refuses. At the moment there is a renewed interest in the appropriate method for the inclusion of residual samples in biobanks. The expansion of biobanks and rapid developments in biomedical research underscore the need to evaluate the proper procedure. In this article we revisit the arguments in favor and against opt-in and opt-out methods for residual tissue research. We conclude firstly that an opt-out method is only justifiable when certain conditions are met: (1) awareness has to be raised, (2) sufficient information has to be provided, and (3) a genuine possibility to object has to be offered. An opt-out procedure that fulfills these conditions can be called a "thick" opt-out method. As a consequence, the dichotomy between opt-in and opt-out is less stark than usually suggested, as both methods require a certain amount of effort. Secondly, we conclude that because of the diversity of tissue and research, not every situation can be treated alike. There are at least four situations that require opt-in procedures: (1) research with higher risks or increased burdens, (2) the use of controversial or high-impact techniques, (3) research on sensitive tissue types, and (4) research involving vulnerable patients. We suggest that further interdisciplinary debate should answer the question when to opt-in or when to opt-out.http://europepmc.org/articles/PMC3415320?pdf=render
spellingShingle Noor A A Giesbertz
Annelien L Bredenoord
Johannes J M van Delden
Inclusion of residual tissue in biobanks: opt-in or opt-out?
PLoS Biology
title Inclusion of residual tissue in biobanks: opt-in or opt-out?
title_full Inclusion of residual tissue in biobanks: opt-in or opt-out?
title_fullStr Inclusion of residual tissue in biobanks: opt-in or opt-out?
title_full_unstemmed Inclusion of residual tissue in biobanks: opt-in or opt-out?
title_short Inclusion of residual tissue in biobanks: opt-in or opt-out?
title_sort inclusion of residual tissue in biobanks opt in or opt out
url http://europepmc.org/articles/PMC3415320?pdf=render
work_keys_str_mv AT nooraagiesbertz inclusionofresidualtissueinbiobanksoptinoroptout
AT annelienlbredenoord inclusionofresidualtissueinbiobanksoptinoroptout
AT johannesjmvandelden inclusionofresidualtissueinbiobanksoptinoroptout